Minerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their price objective on shares of Minerva Neurosciences from $11.00 to $7.00 and set a neutral rating on the stock in a report on Thursday, May 2nd.

Minerva Neurosciences Trading Down 3.2 %

NERV opened at $2.44 on Friday. The company has a market cap of $17.06 million, a price-to-earnings ratio of -0.55 and a beta of 0.27. The company’s 50 day moving average is $2.51 and its 200 day moving average is $5.04. Minerva Neurosciences has a 12-month low of $2.29 and a 12-month high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.07. As a group, analysts predict that Minerva Neurosciences will post -1.89 EPS for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.